scholarly journals Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantation

Haematologica ◽  
2007 ◽  
Vol 92 (6) ◽  
pp. 850-853 ◽  
Author(s):  
C. Rose ◽  
O. Ernst ◽  
B. Hecquet ◽  
P. Maboudou ◽  
P. Renom ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Stem Cell ◽  
Magnetic Resonance ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Iron Overload ◽  
Resonance Imaging ◽  
Hematopoietic Stem ◽  
Long Term Survivors

Comparison of Pharmaceutical Effect of Alemtuzumab and Natalizumab and Their Side Effects in Treatment of Various Stages of Multiple Sclerosis Patients.

2021 ◽  
Vol 20 ◽  
Author(s):  
Mostafa Mohammadi
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Stem Cell ◽  
Side Effects ◽  
Magnetic Resonance ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Resonance Imaging ◽  
Hematopoietic Stem ◽  
Before And After

Background: Multiple sclerosis (MS) is an autoimmune and inflammatory disease in which the body mistakenly attacks the myelin, the sheath of nerve cells in the brain and spinal cord, causing ulcers. This damage to myelin disrupts the transmission of neural messages to the nervous system. This study aimed to compare the pharmacological effect of Alemtuzumab and Natalizumab in treating various stages of MS patients and the side effects of their use. Autologous hematopoietic stem cell transplantation has also been studied as the best current treatment for MS. Methods: In this study, 425patients with MS were examined and categorized into different groups according to their disease stages. Among the people studied, 183 were men, and 242 were women. Patients with primary progressive MS (PPMS) has divided into groups A and B, patients with relapsing-remitting MS (RRMS) in groups C and D, and patients with secondary progressive MS (SPMS) in groups E and F. According to the classification, Alemtuzumab drug prescribed for patients in groups A and C and E, and Natalizumab for B and D and E groups. To more accurately examine patients' condition, a criterion called the large-scale disability status was defined, calculated before and after treatment. Hence, the relationship between the number of head magnetic resonance imaging with the lesions created in patients, recurrence time, and recurrence rate before and after treatment investigated. Results: The EDSS the coefficient was significantly lower in RRMS patients than in PPMS and SPMS patients. After 12 months of treatment, The EDSS coefficient of RRMS patients treated with Natalizumab was significantly lower than patients treated with Alemtuzumab. Also, which was the difference between this coefficient before. Moreover, after treatment was significantly higher, Alemtuzumab, this result indicates the direct effect and a positive function of Natalizumab in this group of patients. Due to Natalizumab's use, the recurrence rate of RRMS-D was significantly lower than that of RRMS-C. After 12 months of treatment, there was a significant decrease in the lesion's number on magnetic resonance imaging of the head and the RRMS-D group time of recurrence. Conclusion: According to the results, the efficacy of Natalizumab in treating RRMS patients was better than Alemtuzumab, while there were no significant differences between other stages of MS patients. Also, the autologous hematopoietic stem cell transplantation method is more effective than Alemtuzumab and Natalizumab to use as the best treatment for patients with MS can give a theoretical and clinical guide for various stages of MS treatment and provide them to specialists.

scholarly journals Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation

Blood ◽  
2020 ◽  
Vol 135 (18) ◽  
pp. 1548-1559 ◽  
Author(s):  
Steffen Boettcher ◽  
C. Matthias Wilk ◽  
Jochen Singer ◽  
Fabian Beier ◽  
Elodie Burcklen ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Clonal Hematopoiesis ◽  
Increased Risk ◽  
Long Term Survivors

Abstract Clonal hematopoiesis (CH) is associated with age and an increased risk of myeloid malignancies, cardiovascular risk, and all-cause mortality. We tested for CH in a setting where hematopoietic stem cells (HSCs) of the same individual are exposed to different degrees of proliferative stress and environments, ie, in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their respective related donors (n = 42 donor-recipient pairs). With a median follow-up time since allo-HSCT of 16 years (range, 10-32 years), we found a total of 35 mutations in 23 out of 84 (27.4%) study participants. Ten out of 42 donors (23.8%) and 13 out of 42 recipients (31%) had CH. CH was associated with older donor and recipient age. We identified 5 cases of donor-engrafted CH, with 1 case progressing into myelodysplastic syndrome in both donor and recipient. Four out of 5 cases showed increased clone size in recipients compared with donors. We further characterized the hematopoietic system in individuals with CH as follows: (1) CH was consistently present in myeloid cells but varied in penetrance in B and T cells; (2) colony-forming units (CFUs) revealed clonal evolution or multiple independent clones in individuals with multiple CH mutations; and (3) telomere shortening determined in granulocytes suggested ∼20 years of added proliferative history of HSCs in recipients compared with their donors, with telomere length in CH vs non-CH CFUs showing varying patterns. This study provides insight into the long-term behavior of the same human HSCs and respective CH development under different proliferative conditions.

Hematopoietic Stem Cell Transplantation and Secondary Primary Malignancies in Taiwan

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4219-4219 ◽  
Author(s):  
Chia-Jen Liu ◽  
Kuo-Wei Chen ◽  
Yu-Wen Hu ◽  
Ying-Chung Hong ◽  
Yu-Chung Huang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Soft Tissue ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Hematological Malignancies ◽  
Soft Tissue Sarcomas ◽  
Cancer Development ◽  
Hematopoietic Stem ◽  
Long Term Survivors

Abstract Abstract 4219 Objectives Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many hematological disorders. The improvement of HSCT may lead to longer overall survival of patients with catastrophic illness and the risk of secondary cancer development become an emerging issue in long-term survivors. Patients and Methods We conducted a nationwide population-based study of 1,881 patients with hematologic diseases undergoing HSCT between January, 1997 and January, 2007 using Taiwan's National Health Insurance Research database. Performing HSCT to treat non-hematological diseases were excluded. All patients were followed until solid cancer development, death, or the end of 2010. We did not put hematological malignancies as endpoint because solid tumors and hematological malignancies might have different carcinogensis mechanism. We used standardized incidence ratios (SIRs) to compare patterns of cancer incidence in patients with those of the general population. Multivariate analysis was undertaken using Cox proportional-hazards regression using a forward selection, likelihood ratio model to identify independent predictors of cancer development among patients after HSCT. Results We observed a total of 8,753.87 person-years in this study. Patients received HSCT had a significant increased risk of developing any kind of cancer (SIR 1.77, 95% confidence interval [CI] 1.15 – 2.62; p = 0.011). Specifically, patients after HSCT had increased cancer incidence of head and neck cancer (SIR 3.96, 95% CI 1.90 – 7.29; p < 0.001) and bone and soft tissue sarcomas (SIR 10.08, 95% CI 1.22 – 36.42; p = 0.035). In subgroup analyses, cancers were more likely to develop in patients aged 0 – 19 years (SIR 22.31, 95% CI 4.60 – 65.20; p < 0.001), and those who survived more than 5 years after HSCT (SIR 3.30, 95% CI 1.96 – 5.22; p < 0.001). Conclusion Our study demonstrates an increased incidence of cancer development in patients after HSCT, especially malignancies of head and neck and also bone and soft tissue sarcomas. Patients aged 0 – 19 years and those survived more than 5 years after HSCT have a higher incidence of developing cancer comparing to normal population. HSCT long-term survivors should therefore be monitored more carefully for cancer development and targeted with preventive intervention strategies. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document